Welcome to our dedicated page for Acrivon Therapeutics news (Ticker: ACRV), a resource for investors and traders seeking the latest updates and insights on Acrivon Therapeutics stock.
Acrivon Therapeutics, Inc. (Nasdaq: ACRV) is a clinical stage biopharmaceutical company that regularly issues news about its precision oncology pipeline and Generative Phosphoproteomics AP3 platform. Company announcements describe progress for its lead CHK1/CHK2 inhibitor ACR-368 in a registrational-intent Phase 2 or Phase 2b trial in endometrial cancer, as well as updates on ACR-2316, a WEE1/PKMYT1 inhibitor in Phase 1 development, and AP3-enabled preclinical programs such as the CDK11-targeting candidate ACR-6840.
News releases from Acrivon often cover interim clinical data, including response rates and tumor shrinkage in AP3-prioritized solid tumor types, details on dose-escalation cohorts, and observations of drug target engagement based on AP3 profiling. The company also reports on regulatory designations, such as FDA Fast Track status for ACR-368 monotherapy in endometrial cancer and FDA Breakthrough Device designation for the ACR-368 OncoSignature assay, as well as trial design elements like biomarker-selected and biomarker-unselected arms and combinations with ultra-low dose gemcitabine.
Investors and observers following ACRV news can expect updates on Acrivon’s presentations at scientific conferences, including AACR and AACR-NCI-EORTC, where the company highlights AP3-based mechanistic data, the AP3 KaiSR generative AI model, and pharmacodynamic insights for ACR-2316 and other candidates. The company also issues periodic financial results and business highlights, summarizing cash resources, research and development activities, and anticipated clinical and regulatory milestones for its AP3-enabled pipeline.
This ACRV news page aggregates these press releases and related coverage, providing a centralized view of Acrivon’s reported clinical progress, platform developments, and corporate updates over time.
Acrivon Therapeutics (Nasdaq: ACRV) announced a virtual investor event on September 14, 2024, to review positive Phase 2 clinical data of ACR-368 presented at ESMO and pipeline progress. The event will highlight:
1. Updated ACR-368 clinical data in endometrial cancer from the ongoing registrational intent Phase 2b study
2. Updates on lead assets ACR-368, ACR-2316, and the AP3 platform
3. Previous data showed a 50% confirmed response rate across ovarian and endometrial cancer patients
4. Enrollment for endometrial cancer patients is progressing ahead of schedule
5. The study represents the first potential approval opportunity for ACR-368
The ESMO poster presentation details and webcast information are provided in the announcement.
Acrivon Therapeutics (Nasdaq: ACRV) reported Q2 2024 financial results and business highlights. Key points include:
- Planned webcast in September 2024 during ESMO conference to update on clinical programs and AP3 platform progress
- Initial positive clinical data for ACR-368 showed 50% overall response rate in gynecological cancers
- On track to initiate Phase 1 study for ACR-2316 in Q4 2024
- Executed $130 million private placement financing
- Q2 2024 net loss of $18.8 million, compared to $13.9 million in Q2 2023
- Cash position of $220.4 million, expected to fund operations into second half of 2026
Acrivon Therapeutics, a clinical-stage biopharmaceutical company specializing in precision oncology, will present at the Jefferies Global Healthcare Conference on June 5, 2024. The company's CEO, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat at 9:30 a.m. ET. The event will be webcast live and accessible via the company's investor relations page. The presentation will utilize Acrivon's proprietary AP3 platform, which identifies patients whose tumors are likely to respond to specific oncology treatments. A replay of the webcast will be available for 30 days.
Acrivon Therapeutics reported its first quarter 2024 financial results and business highlights on May 14, 2024. The company, which leverages its proprietary Acrivon Predictive Precision Proteomics (AP3) platform for developing precision oncology medicines, made significant strides in its clinical and preclinical pipeline.
Key achievements include the validation of the AP3 platform's ACR-368 OncoSignature assay, demonstrating a 50% overall confirmed response rate in patients with ovarian and endometrial cancer. The company has also accelerated the IND timeline for ACR-2316, a new WEE1/PKMYT1 inhibitor, with clinical trials expected to begin in Q4 2024. Financially, Acrivon reported a net loss of $16.5 million for Q1 2024, compared to $12.8 million in Q1 2023. The company raised $130 million in a private placement, extending its cash runway into H2 2026.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Acrivon Therapeutics (ACRV)?
What is the market cap of Acrivon Therapeutics (ACRV)?
